Acyclovir Therapy in Children with Herpes Simplex Virus Infections

Standard Dosing for Common HSV Infections

• The Centers for Disease Control and Prevention (CDC) recommends oral acyclovir: 20 mg/kg per dose (maximum 400 mg/dose) three times daily for 5-10 days for mild to moderate disease including herpetic gingivostomatitis, eczema herpeticum, or herpetic whitlow 1, 2, 3, 4
• Therapy should be continued until lesions completely heal, not just until improvement begins 2, 3, 4
• Clinical improvement should be monitored within 48-72 hours 2, 3, 4

Severe Disease Management

• For severe HSV infections requiring hospitalization, the CDC recommends starting with intravenous acyclovir 5-10 mg/kg per dose three times daily 1, 2, 4
• After lesions begin to regress, transition to oral acyclovir at the same weight-based dosing to complete the treatment course 2, 4
• For disseminated HSV disease or encephalitis, use intravenous acyclovir 10 mg/kg/dose or 500 mg/m²/dose three times daily for 21 days 1

Safety Profile in Young Children

• The most common adverse effect of acyclovir in children is neutropenia, occurring in approximately 21-46% of infants on prolonged therapy, though typically self-limited 1
• Ensure adequate hydration to prevent crystalluria and renal toxicity 1, 2
• Dose adjustment is required if renal insufficiency develops 1

Important Clinical Considerations

• The American Academy of Pediatrics and the CDC recommend initiating treatment within the first 3 days of symptom onset for maximum efficacy, as peak viral replication occurs in the first 24 hours after lesion onset 3
• Pediatric experience with oral acyclovir in children under 2 years is more limited than in older children, but the available data support its safety and efficacy 1

Acyclovir-Resistant HSV

• If the child fails to respond after 5-7 days of appropriate acyclovir therapy, consider intravenous foscarnet 40 mg/kg per dose three times daily for acyclovir-resistant HSV 1, 2, 3, 4

Recurrent HSV Disease

• For children with frequent or severe recurrences, daily suppressive therapy with oral acyclovir can be considered 1, 5, 6
• The recommendations for preventing recurrence in adults apply to children as well 6

Common Pitfalls to Avoid

• The CDC and other medical societies recommend not using topical antivirals alone as they cannot reach the site of viral reactivation or impact the host immune response 3
• Do not stop treatment early when symptoms improve; continue until complete healing occurs 2, 3, 4

Acyclovir Dosing for Eczema Herpeticum in Children

Special Population: Neonates

• For neonates with eczema herpeticum, the Centers for Disease Control and Prevention, as reported in the MMWR Recommendations and Reports, recommends using higher doses of intravenous acyclovir 20 mg/kg IV every 8 hours, as recommended for neonatal HSV infections 7
• Neonatal skin, eye, or mouth disease requires acyclovir 20 mg/kg IV three times daily for 14 days, according to the MMWR Recommendations and Reports 7

Acyclovir Dosing and Management for Pediatric HSV‑1 Gingivostomatitis

Dosage Recommendations

• For children with HSV‑1 gingivostomatitis, the CDC recommends oral acyclovir 20 mg/kg per dose (maximum 400 mg) administered three times daily for 5–10 days, continuing until all lesions have completely healed. [8][9]

Dose Calculation and Formulation

• The dose is calculated by multiplying the child’s weight (kg) by 20 mg/kg; the dose must not exceed 400 mg per administration. [8][9]
• Acyclovir oral suspension is supplied as 200 mg per 5 mL; therefore, the required volume (mL) = (prescribed dose ÷ 200 mg) × 5 mL. [8][9]

Example Dose Table

All values derived from CDC dosing guidance. [8][9]

Treatment Duration and Endpoint

• Therapy should be continued for 5–10 days, with the primary endpoint being complete healing of all oral lesions rather than merely symptom improvement. [8][9]

Severity‑Based Management Algorithm

Mild to Moderate Disease (outpatient)

• Use oral acyclovir at the weight‑based dose (20 mg/kg, max 400 mg) TID, ensuring adequate hydration. [8][9]

Moderate to Severe Disease (hospitalized)

• Initiate intravenous acyclovir 5–10 mg/kg per dose TID; once lesions begin to regress, switch to oral acyclovir using the same weight‑based dosing to complete the course. [8][9]

Treatment Continuation Guidance

• Do not discontinue acyclovir before complete lesion healing; stopping early may lead to suboptimal outcomes. [8][9]

Evidence level: not explicitly stated in the CDC recommendations.

Acyclovir Use for Herpes Simplex Virus Infections in Children

Outpatient Management of Mild‑to‑Moderate HSV

• The CDC recommends oral acyclovir at 20 mg/kg per dose (maximum 400 mg) three times daily for 5–10 days for children with mild or moderate HSV infections treated as outpatients【@1】.

Hospitalized Children With Severe HSV

• For children requiring hospitalization, the CDC advises intravenous acyclovir 5–10 mg/kg per dose three times daily【@1】【@2】.
• Once lesions begin to regress, the CDC recommends transitioning to oral acyclovir using the same weight‑based dosing to complete the treatment course【@1】.

Disseminated Disease or HSV Encephalitis

• The CDC specifies intravenous acyclovir 10 mg/kg per dose (or 500 mg/m² per dose) three times daily for 21 days for disseminated HSV infection or encephalitis【@2】.

Genital Herpes in Pediatric Patients

• For children weighing less than 45 kg, the CDC recommends acyclovir 20 mg/kg per dose (maximum 400 mg) three times daily for 5–14 days【@1】.
• For adolescents weighing 45 kg or more, the CDC recommends acyclovir 400 mg twice daily for 5–14 days【@1】.

Renal Function Considerations

• The CDC states that dose adjustment of acyclovir is required if renal insufficiency develops【@2】.
• The CDC notes that acyclovir is primarily eliminated by the kidneys, underscoring the need for renal monitoring【@2】.

Management of Treatment Failure

• If a child shows no clinical response after 5–7 days of appropriate oral acyclovir therapy, the CDC advises using intravenous foscarnet 40 mg/kg per dose three times daily for acyclovir‑resistant HSV infections【@1】.

Regulatory Approval and Evidence Base

• The FDA approved oral acyclovir for treatment of varicella in otherwise healthy children in 1992, based on placebo‑controlled, double‑blind trials that demonstrated clinical benefit without serious adverse events【@3】.

Acyclovir Oral Suspension Dosing and Preparation

Concentration and Volume Calculation

• The commercially available acyclovir oral suspension is formulated at a concentration of 6 mg per milliliter, allowing precise weight‑based dosing for children. 10
• To determine the required volume, divide the prescribed dose (in mg) by the suspension concentration (6 mg/mL). For example, a 400 mg dose corresponds to approximately 67 mL of suspension. 10

Compounding When Suspension Is Unavailable

• If the ready‑made suspension cannot be obtained, pharmacies may compound a 6 mg/mL acyclovir suspension from tablets by following the manufacturer’s label instructions, ensuring an equivalent concentration for pediatric dosing. 10

CDC Guideline for Antiviral Management of Herpetic Gingivostomatitis in Children (6 months – 5 years)

Outpatient Antiviral Therapy

• Oral acyclovir 20 mg/kg three times daily (maximum 400 mg per dose) for 5–10 days is the CDC‑recommended regimen for convenience in children; pediatric trial data for this specific schedule are less robust than for the 15 mg/kg five‑times‑daily regimen. 11
• Adequate oral hydration must be maintained throughout treatment because dehydration is the primary complication that can necessitate hospitalization. 11

Inpatient Management

• Initiate intravenous acyclovir at 5–10 mg/kg per dose three times daily for children who cannot maintain oral intake due to severe oral pain or extensive lesions. 11
• Switch to oral acyclovir using the same weight‑based dosing once oral lesions begin to regress and the child can tolerate oral fluids. 11
• Hospitalization is indicated when extensive oral lesions prevent adequate intake, even if the child otherwise appears stable. [12][13]

Treatment Duration and Clinical Endpoint

• Continue antiviral therapy for 5–10 days, aiming for complete healing of all oral lesions rather than stopping at a predetermined time point. 11
• Do not discontinue acyclovir early if symptoms improve; therapy should be maintained until full lesion resolution to avoid relapse. 11

Safety Monitoring

• Ensure sufficient hydration to prevent acyclovir crystalluria and renal toxicity; monitor renal function during therapy. 11
• Adjust acyclovir dose if renal insufficiency develops, as the drug is eliminated primarily by the kidneys. 11

Management of Antiviral Resistance

• If clinical response is absent after 5–7 days of appropriate acyclovir, consider the possibility of acyclovir‑resistant HSV (rare in immunocompetent children).
• For confirmed resistant HSV, administer intravenous foscarnet 40 mg/kg per dose three times daily until complete lesion resolution. 11

Special Considerations for Neonates (≤ 28 days)

• Neonates with skin, eye, or mouth disease require higher‑dose IV acyclovir: 20 mg/kg every 8 hours for 14 days. [12][13]
• Neonates with CNS involvement need 21 days of IV acyclovir, with repeat CSF HSV PCR performed on days 19–21 before discontinuation. [12][13]